A 4-minute youtube video was posted today by "EUA for Leronlimab - THE COVID Lifeline". Comments are turned off and it has been viewed 427 times so far.
It looks like a good overview to me, but you high-tech posters may find some erroneous statements.
It appears that the purpose of the video is to create more pressure on Woodcock. Not sure if it will lead to much of an impact with the FDA, but interesting short video anyway. If you wanted to educate someone about Leronlimab who had never heard of it, this looks to me like a good starting point.
https://www.youtube.com/watch?v=W84-ORWbKPM
The following narrative is shown beneath the introduction.
Leronlimab by CytoDyn CYDY, saves lives for COVID patients. COVID longhaulers now have hope for a COVID cure. The FDA is reviewing Leronlimab now for a EUA for COVID.
What will your contribution be in this generational defining moment? Will you step up and demand the FDA issue a EUA for this top-performing drug? Will you ask the FDA why Big Pharma's drugs have EUAs, while CytoDyn with 22 employees and a better drug (Leronlimab) does not? How many more patients will die needlessly before you get involved and demand more from the FDA? Please do all you can to demand the FDA give a EUA for Leronlimab (Vyrologix) the best-performing drug with the best safety profile - and share this with the FDA, the medical community, politicians, media, and any influencers.
Quite simply, leronlimab saved lives and helped patients recover faster.
No other drug thus far has shown a major survival benefit when used to treat the severe and critical COVID-19 patient population, except dexamethasone.
When given with dexamethasone, leronlimab use led to further improvement of mortality rate among patients suffering from severe to critical COVID-19
COVID-19: LERONLIMAB FOR SEVERE TO CRITICAL COVID-19 - The Recent Phase2b/3 Trial evaluated the safety and efficacy of leronlimab in treating severe and critical COVID-19
26.1% REDUCTION IN MORTALITY RATE VS. DEXAMETHASONE ALONE
Among patients who received dexamethasone, the addition of leronlimab was associated with a 26.1% relative reduction of in mortality rate by day 28 (absolute risk reduction of 5.7%, p value = 0.0552)
28.1% REDUCTION IN MORATLITY RATE VS. STANDARD OF CARE (SoC)
Among those who received institutional SoC, the addition of leronlimab was associated with a 28.1% relative reduction of mortality rate by day 28 (absolute risk reduction of 6.5%, p value = 0.0319)
SHORTENED HOSPITAL STAY
Leronlimab also shortened time to recovery by 5.5 days among critically ill patients. (p value = 0.0050)
This would translate to a significant cost savings for patients, hospitals and insurance companies.
CytoDyn recently finished a phase 2b/3 trial studying the efficacy of leronlimab in treating severe and critical COVID-19 patients. The trial demonstrated favorable results, and they have filed a request for emergency use authorization (EUA) for leronlimab to treat critically ill COVID-19 patients on mechanical ventilation with the FDA.
COVID-19: LERONLIMAB FOR MILD TO MODERATE COVID-19 - A previous phase 2 study was completed in 2020.
83% DECREASE IN HOSPITALIZATION Early treatment with Leronlimab among mild to moderately ill COVID-19 patients decreased the incidence of hospitalization by 83% when compared to the placebo group.
COVID-19: POST ACUTE COVID SYNDROME (PACS) - A phase 2 trial studying safety and efficacy of leronlimab among patients with “long hauler” symptoms is currently on-going.
ADDITIONAL FAVORABLE DRUG PROFILE - Much of what we know about Leronlimab comes from more than two decades of clinical trials studying its safety and efficacy among HIV patients.
PROVEN SAFETY The drug’s safety profile is well-documented among 1000+ study subjects, including some HIV patients having follow-up observations ranging from 1 to 5 years.
A recently approved IL-6 blocker used to treat severe to critical hospitalized COVID-19 patients requiring mechanical ventilation, reduced mortality by ONLY 2% compared to the placebo group. In contrast, leronlimab demonstrated a reduction of 24% in mortality compared to the SoC treated group, which is 12 TIMES BETTER in reducing all-cause mortality for critically ill COVID-19 patients.
Leronlimab is an exciting new drug for covid. This is simply the best drug available to fight COVID in Brazil, the Philippines, Canada, the USA, in Hungry or anywhere where regulators want to save the lives of its citizens. Demand that the FDA issue an EUA for Leronlimab now. Give EUA to Leronlimab and save the lives of thousands of critical Covid-19 patients. Leronlimab has been proven completely safe with no drug interactions.
Where are the hospitals, the clinical trial sites? Montefiore Medical Center - Bronx, NY, Novant Health - Winston-Salem, NC, UCLA Medical Center - Los Angeles, CA, Baylor Scott & White Health - Dallas, TX, Baylor College of Medicine - Houston, TX, University of Texas Health - Houston, TX, Beth Israel Deaconess Medical Center, Harvard Medical School - Boston, MA, St. Barnabas Medical Center - Livingston, New Jersey, Atlantic Health - Morristown, NJ, OHSU - Portland, OR, Ohio Health - Columbus, OH, Advanced Cardiovascular - Alexander City, Alabama, St. Jude Medical Center - Fullerton, California, James A. Haley Veterans' Hospital - Tampa, FL, Center for Advanced Research & Education (CARE) - Gainesville, Georgia, Atlantic Health System Hospital - Morristown, New Jersey, Holy Name Medical Center - Teaneck, New Jersey, New York Community Hospital of Brooklyn - Brooklyn, New York, Good Samaritan Hospital - Corvallis, OR.
It looks like a good overview to me, but you high-tech posters may find some erroneous statements.
It appears that the purpose of the video is to create more pressure on Woodcock. Not sure if it will lead to much of an impact with the FDA, but interesting short video anyway. If you wanted to educate someone about Leronlimab who had never heard of it, this looks to me like a good starting point.
https://www.youtube.com/watch?v=W84-ORWbKPM
The following narrative is shown beneath the introduction.
Leronlimab by CytoDyn CYDY, saves lives for COVID patients. COVID longhaulers now have hope for a COVID cure. The FDA is reviewing Leronlimab now for a EUA for COVID.
What will your contribution be in this generational defining moment? Will you step up and demand the FDA issue a EUA for this top-performing drug? Will you ask the FDA why Big Pharma's drugs have EUAs, while CytoDyn with 22 employees and a better drug (Leronlimab) does not? How many more patients will die needlessly before you get involved and demand more from the FDA? Please do all you can to demand the FDA give a EUA for Leronlimab (Vyrologix) the best-performing drug with the best safety profile - and share this with the FDA, the medical community, politicians, media, and any influencers.
Quite simply, leronlimab saved lives and helped patients recover faster.
No other drug thus far has shown a major survival benefit when used to treat the severe and critical COVID-19 patient population, except dexamethasone.
When given with dexamethasone, leronlimab use led to further improvement of mortality rate among patients suffering from severe to critical COVID-19
COVID-19: LERONLIMAB FOR SEVERE TO CRITICAL COVID-19 - The Recent Phase2b/3 Trial evaluated the safety and efficacy of leronlimab in treating severe and critical COVID-19
26.1% REDUCTION IN MORTALITY RATE VS. DEXAMETHASONE ALONE
Among patients who received dexamethasone, the addition of leronlimab was associated with a 26.1% relative reduction of in mortality rate by day 28 (absolute risk reduction of 5.7%, p value = 0.0552)
28.1% REDUCTION IN MORATLITY RATE VS. STANDARD OF CARE (SoC)
Among those who received institutional SoC, the addition of leronlimab was associated with a 28.1% relative reduction of mortality rate by day 28 (absolute risk reduction of 6.5%, p value = 0.0319)
SHORTENED HOSPITAL STAY
Leronlimab also shortened time to recovery by 5.5 days among critically ill patients. (p value = 0.0050)
This would translate to a significant cost savings for patients, hospitals and insurance companies.
CytoDyn recently finished a phase 2b/3 trial studying the efficacy of leronlimab in treating severe and critical COVID-19 patients. The trial demonstrated favorable results, and they have filed a request for emergency use authorization (EUA) for leronlimab to treat critically ill COVID-19 patients on mechanical ventilation with the FDA.
COVID-19: LERONLIMAB FOR MILD TO MODERATE COVID-19 - A previous phase 2 study was completed in 2020.
83% DECREASE IN HOSPITALIZATION Early treatment with Leronlimab among mild to moderately ill COVID-19 patients decreased the incidence of hospitalization by 83% when compared to the placebo group.
COVID-19: POST ACUTE COVID SYNDROME (PACS) - A phase 2 trial studying safety and efficacy of leronlimab among patients with “long hauler” symptoms is currently on-going.
ADDITIONAL FAVORABLE DRUG PROFILE - Much of what we know about Leronlimab comes from more than two decades of clinical trials studying its safety and efficacy among HIV patients.
PROVEN SAFETY The drug’s safety profile is well-documented among 1000+ study subjects, including some HIV patients having follow-up observations ranging from 1 to 5 years.
A recently approved IL-6 blocker used to treat severe to critical hospitalized COVID-19 patients requiring mechanical ventilation, reduced mortality by ONLY 2% compared to the placebo group. In contrast, leronlimab demonstrated a reduction of 24% in mortality compared to the SoC treated group, which is 12 TIMES BETTER in reducing all-cause mortality for critically ill COVID-19 patients.
Leronlimab is an exciting new drug for covid. This is simply the best drug available to fight COVID in Brazil, the Philippines, Canada, the USA, in Hungry or anywhere where regulators want to save the lives of its citizens. Demand that the FDA issue an EUA for Leronlimab now. Give EUA to Leronlimab and save the lives of thousands of critical Covid-19 patients. Leronlimab has been proven completely safe with no drug interactions.
Where are the hospitals, the clinical trial sites? Montefiore Medical Center - Bronx, NY, Novant Health - Winston-Salem, NC, UCLA Medical Center - Los Angeles, CA, Baylor Scott & White Health - Dallas, TX, Baylor College of Medicine - Houston, TX, University of Texas Health - Houston, TX, Beth Israel Deaconess Medical Center, Harvard Medical School - Boston, MA, St. Barnabas Medical Center - Livingston, New Jersey, Atlantic Health - Morristown, NJ, OHSU - Portland, OR, Ohio Health - Columbus, OH, Advanced Cardiovascular - Alexander City, Alabama, St. Jude Medical Center - Fullerton, California, James A. Haley Veterans' Hospital - Tampa, FL, Center for Advanced Research & Education (CARE) - Gainesville, Georgia, Atlantic Health System Hospital - Morristown, New Jersey, Holy Name Medical Center - Teaneck, New Jersey, New York Community Hospital of Brooklyn - Brooklyn, New York, Good Samaritan Hospital - Corvallis, OR.
9
